Home / Guides by goal / Skin aging
Best Peptides for Skin and Aging: What the Evidence Shows
Do collagen peptides, peptide creams or GHK-Cu work for skin aging? What the trials show, why the best studies disagree, and what FDA doesn't review.
The short answer
No skin product built on peptides has strong, consistent, independent evidence that it reverses skin aging. Oral collagen has the most trials, and pooled results look positive, but one meta-analysis found the benefit disappeared when it looked only at higher-quality studies or studies without industry funding. A few small trials of single-ingredient creams report fewer wrinkles, over weeks. The one controlled trial of GHK-Cu we could read found no objective improvement.
None of these is an FDA-approved drug for skin aging. That label means different things for each, explained below.
On this page
Skin-care marketing leans on peptides more than on trials. Here is what the evidence shows for oral collagen peptides, anti-wrinkle creams and the copper peptide GHK-Cu, and why the best-quality studies often disagree with the headline results.
The ranking, by strength of evidence
| Peptide | U.S. status | Strongest evidence |
|---|---|---|
| 1. Collagen peptides | Limited human data | |
| 2. Topical cosmetic peptides | Limited human data | |
| 3. GHK-Cu | Limited human data |
How do we decide what is “best”?
“Best” means best evidence, not best marketing. We rank by the type of evidence first, then its quality and its result. For skin and aging we look for:
- Randomized, controlled trials in people, with objective measures such as wrinkle or elasticity assessments, not only self-reported satisfaction.
- Independent and high-quality studies. When the quality of a trial or its funding changes the result, we say so.
- A product that is clearly one thing. If a cream has several active ingredients, we cannot credit the result to one peptide.
- Lab and animal findings are not clinical evidence. They can suggest how something might work.
Ordered by the strength of the evidence that it helps with this goal: the type of study first, then its quality and its result. A rank isn’t a recommendation.
| Rank | What | Best human evidence | What limits it |
|---|---|---|---|
| 1 | Oral collagen peptides | Many randomized trials; pooled results show better hydration and elasticity | In one 2025 meta-analysis, higher-quality and non-industry-funded studies showed no effect |
| 2 | Topical cosmetic peptides (single-ingredient) | Two small randomized trials report fewer wrinkles or less roughness | Small, short, little detail on size of effect |
| 3 | GHK-Cu | One small randomized trial | No objective improvement; only higher satisfaction |
The gap between ranks 1 and 2 is small, and the order is a judgment about quantity of trials, not an endorsement. None clears a strong-evidence bar.
What does the evidence say about oral collagen peptides?
Oral collagen is hydrolyzed collagen sold as a dietary supplement, usually powders or capsules.
| Review | Scope | Result |
|---|---|---|
| Am J Med 2025 | 23 randomized trials, 1,474 participants | Pooled: better hydration, elasticity and wrinkles. No effect in studies without industry funding, and none in high-quality studies. The authors conclude there is no clinical evidence supporting its use to prevent or treat skin aging |
| Nutrients 2023 | 26 randomized trials, 1,721 patients | Better hydration and elasticity; the authors identify biases |
| Front Med 2026 | 19 randomized trials, 1,341 participants, oral and topical peptides | Modest effect on wrinkles, driven by the oral products; elasticity and density inconsistent; calls for larger trials |
| Int J Dermatol 2021 | 19 randomized trials, 1,125 participants | Favorable on hydration, elasticity and wrinkles |
Which result should you believe?
Both. There are many trials, and their combined effect is positive. But the 2025 analysis that separated studies by funding and quality found the effect vanished. That is a single analysis, so it does not settle the question. It does mean that “meta-analyses show it works” is an incomplete summary.
Other cautions
- Studies used different products, so “collagen” results are not interchangeable.
- We did not review whether collagen you swallow reaches your skin. A lab finding that collagen peptides stimulate collagen in cells does not show younger-looking skin.
- Pooled trials describe it as generally well tolerated. We did not systematically assess contaminants or allergies, and FDA does not check supplements before sale.
What does the evidence say about anti-wrinkle creams with peptides?
These are cosmetic ingredients such as palmitoyl pentapeptide and acetyl hexapeptide in creams and serums. We use chemical names, not brand names, and we do not recommend products.
| Study | Design | Result | Limits |
|---|---|---|---|
| Palmitoyl pentapeptide, Robinson 2005 | 93 women, 12 weeks, split-face, double-blind, against the same cream without the peptide | Fewer wrinkles and fine lines than the vehicle | Only Caucasian women aged 35–55; the abstract gives no size of effect or funding |
| Acetyl hexapeptide, Wang 2013 | 60 participants (3:1 split), 4 weeks, around the eyes | Subjective efficacy 48.9% vs 0%; less roughness | Short, small, small control group |
What we leave out: other studies tested formulas with several active ingredients (an eye cream, an open-label moisturizer, microneedle patches). Results from those cannot be credited to one peptide.
The 2026 Front Med review found the modest wrinkle effect was driven by oral products, and we could not separate the topical effect from its abstract. Cell-culture studies, such as this one in fibroblasts, do not demonstrate a clinical effect.
Our search was limited to PubMed. Unpublished or unindexed industry trials are not included, and “we did not find” is not “it does not exist.”
Cream safety: the studies above and the review describe the products as well tolerated, in small samples and over short periods. We reviewed no long-term systematic safety data. A reaction to a multi-ingredient product could come from any ingredient.
What does the evidence say about GHK-Cu?
GHK-Cu is a small copper-binding peptide, and it is not an FDA-approved drug. The one randomized controlled trial of GHK-Cu on skin that we found and could read does not show a benefit.
| Study | Design | Participants | Result |
|---|---|---|---|
| Miller 2006 | Randomized, skin-care products after CO2 laser resurfacing | 13 completed | No objective difference in redness, wrinkles or skin quality. Greater self-reported satisfaction (p=0.04) |
Context for that result:
- It is small. Thirteen people cannot rule out a modest effect, and it tested a post-laser setting, not everyday aging.
- We could not rule out other studies. Our PubMed search found no other controlled skin trial of GHK-Cu with readable results. A 2026 systematic review reports that GHK-Cu reduced wrinkle volume and depth compared with controls; its abstract does not name that study, and it notes few well-designed trials.
- Satisfaction is not an objective result. In a small study, a participant’s own impression can reflect expectation as much as skin change.
- Reviews. A 2025 review of topical GHK reports “a surprising absence of clinical studies” of GHK-Cu and a related form in anti-wrinkle products. A 2026 scoping review of six peptides, including GHK-Cu, concluded that their claimed benefits remain unsubstantiated by current human trials. That review is about recovery and performance, not skin.
- Animal and lab work. GHK has been reported to affect collagen production in cells, which is a hypothesis about mechanism. The animal study we reviewed, a rat model of ACL reconstruction (72 animals), found a transient improvement and was not about skin.
What is GHK-Cu’s regulatory status?
It depends on the form. Dated Oct. 31, 2026:
| Form | Status | Source |
|---|---|---|
| Non-injectable, compounded | On FDA’s 503A Category 1 list (substances under evaluation for compounding). It was withdrawn April 22, 2026 and restored when a nominator clarified that only the injectable route was withdrawn | FDA list, May 14, 2026 |
| Injectable, compounded | Not in Category 1. The nomination was withdrawn. FDA cites a risk of immune reactions and “limited data in humans” | FDA |
| FDA advisory committee | FDA says it intends to consult its compounding advisory committee before the end of February 2027 | FDA list |
| HHS interim policy of Oct. 30, 2026 | GHK-Cu is not included | HHS policy, Appendix A |
| 503B outsourcing facilities | Not listed in FDA’s 503B nominations document, updated March 21, 2025. We did not find a later version | FDA 503B list |
Category 1 is not FDA approval, nor a statement that GHK-Cu is safe or effective. Cosmetics containing GHK-Cu fall under the cosmetics rules described below; we have not checked rules specific to GHK-Cu cosmetics.
What does “not FDA-approved” mean for each of these?
It does not mean the same thing across the three.
- Oral collagen is a dietary supplement. FDA has no authority to approve supplements before they are sold, and the company generally does not have to give FDA its safety evidence. The manufacturer is responsible for safety and labeling.
- Peptide creams and serums are generally sold as cosmetics, and the law does not require FDA approval before they are sold, except for color additives. Companies are responsible for safety. The line matters: FDA says that making wrinkles less noticeable by moisturizing is a cosmetic claim, but a product intended to “remove wrinkles or increase the skin’s production of collagen” is a drug or a device. The intended use decides it. “Cosmeceutical” has no legal meaning.
- Compounded GHK-Cu is a pharmacy-made drug. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are marketed.
What are the risks of GHK-Cu?
- Injectable GHK-Cu: FDA flags a risk of immune reactions from aggregation and impurities, and limited human data. Injectable peptides are a different matter from creams and should not be judged by cream studies.
- Topical GHK-Cu: we did not find systematic long-term safety data in our review.
Which claims are not supported?
- “Clinically proven to erase wrinkles.” For GHK-Cu, the one controlled trial we read found no objective improvement. For collagen, one 2025 meta-analysis found no effect in high-quality studies.
- “Works like Botox.” We found no comparison that supports it.
- “Stimulates collagen.” That is a lab finding. FDA treats this kind of claim as a drug claim when it is made about a cosmetic.
- “It regrows hair.” We found no controlled trial of GHK-Cu on scalp hair.
- “Injectable is stronger.” We found no basis for this, and FDA flags risks.
- “Category 1 means FDA-approved.” It does not.
What should you ask a clinician or dermatologist?
- What does the evidence say about the skin concern I have, and which options are FDA-approved for it?
- If a product is sold with anti-aging claims, is it a cosmetic or a supplement, and what independent evidence supports its claims?
- If GHK-Cu is suggested, in what form, who makes it, and what is the evidence for my concern?
- How would we judge whether it is working?
We do not give doses or preparation instructions, and we do not recommend brands or sellers.
Frequently asked questions
Do collagen supplements work for skin?
Pooled trials show small improvements in hydration and elasticity, but a 2025 meta-analysis found no effect when it looked only at higher-quality studies or those without industry funding.
Do peptide creams work for wrinkles?
Two small randomized trials of single-ingredient creams reported benefits over 4 to 12 weeks. Most evidence is from small, short studies, and many tested formulas with several active ingredients.
Do copper peptides work for wrinkles?
The only randomized trial of GHK-Cu on skin we could read found no objective improvement in wrinkles or redness after laser resurfacing, only higher self-reported satisfaction. It was small (13 people).
Is GHK-Cu FDA-approved?
No. It is not an approved drug.
Is injectable GHK-Cu safe?
FDA has flagged a risk of immune reactions and limited human data. Safety has not been established.
Is GHK-Cu part of the new HHS peptide policy?
No. The Oct. 30, 2026 policy names six other peptides.
How did we rank them?
We rank by the type of evidence first, then its quality and its result. If no peptide has good evidence for a goal, we say so.
- Human trialsControlled trials in people, published in a journal, that tested a clinical outcome and showed a benefit. The strongest kind of evidence we report.
- Limited human dataSmall, short or inconclusive human studies, including observational studies, uncontrolled trials and controlled trials that did not show a clinical benefit.
- Animal studiesResults in animals often don’t carry over to people.
- Lab studiesCells or tissue in a dish. An early signal, not an answer.
Sources we checked
- Collagen supplementation and skin aging, meta-analysis of 23 RCTs, Am J Med 2025 (PubMed)PubMed. Accessed .
- Oral collagen and skin, systematic review and meta-analysis of 26 RCTs, Nutrients 2023 (PubMed)PubMed. Accessed .
- Collagen supplementation and skin, meta-analysis, Int J Dermatol 2021 (PubMed)PubMed. Accessed .
- Oral and topical peptides for skin aging, systematic review of 19 RCTs, Front Med 2026 (PubMed)PubMed. Accessed .
- Robinson 2005: palmitoyl pentapeptide split-face trial (PubMed)PubMed. Accessed .
- Wang 2013: acetyl hexapeptide periorbital trial (PubMed)PubMed. Accessed .
- Eye cream containing several actives, 2024 (PubMed)PubMed. Accessed .
- Open-label moisturizer study, n=37, 2015 (PubMed)PubMed. Accessed .
- Microneedle patch study, 2020 (PubMed)PubMed. Accessed .
- Peptide effects in fibroblast cultures (PubMed)PubMed. Accessed .
- Review of topical GHK, BioImpacts 2025 (PubMed)PubMed. Accessed .
- FDA: questions and answers on dietary supplementsFDA. Accessed .
- FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulatedFDA. Accessed .
- FDA: wrinkle treatments and other anti-aging productsFDA. Accessed .
- FDA: is it a cosmetic, a drug, or both?FDA. Accessed .
- Miller 2006: GHK-Cu skin care after CO2 laser resurfacing (PubMed)PubMed. Accessed .
- FDA 503A Category 1 list (updated May 14, 2026)FDA. Accessed .
- FDA: bulk drug substances that may present significant safety risksFDA. Accessed .
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- FDA 503B list of bulk drug substancesFDA. Accessed .
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine, Am J Sports Med 2026 (PubMed)PubMed. Accessed .
- GHK-Cu in a rat ACL reconstruction model (PubMed)PubMed. Accessed .
- GHK-Cu in aesthetic medicine, systematic review, Aesthet Surg J 2026 (PubMed)PubMed. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.